{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:07:21Z","timestamp":1787170041819,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>During the second wave of COVID-19, the incidence of mucormycosis has increased more rapidly. The most common causes attributed to the rise of mucormycosis in COVID-19 are uncontrolled diabetes, the excessive use of corticosteroids, and long-term stays in the intensive care unit, organ or bone marrow transplantation, etc.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To determine the sociodemographic and associated risk factors, pattern of disease, treatment of mucormycosis and outcome of individual at time of discharge and after three months and six months of follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology:<\/jats:title>\n                    <jats:p>This cross-sectional study included all treated mucormycosis cases with prior COVID-19 infection. Data collected from medical records using purposive sampling. Survivors followed up at 3 and 6 months after discharge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In our study, we analyzed 161 mucormycosis cases identified through positive RTPCR\/Rapid Antigen reports. Among them, 72% were males and 28% were females. Diabetes mellitus was present in 71.4% and hypertension in 29.8% of patients. The case-fatality rate was 6.8% at discharge, increasing to 18.6% after 3 months and 28% after 6 months of follow-up. Statistical analysis was conducted using SPSS version 15. This analysis helped us draw meaningful conclusions from the data, highlighting the impact of comorbidities and time on mucormycosis outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Post-COVID mucormycosis in India was primarily observed in patients with uncontrolled diabetes, immunodeficiency due to other comorbidities, and dysfunctional immune systems.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jfmpc.jfmpc_358_23","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T16:10:18Z","timestamp":1696867818000},"page":"2413-2417","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Mucormycosis in COVID-19 patients: A cross-sectional study at IGIMS, Patna"],"prefix":"10.4103","volume":"12","author":[{"given":"Tajwar","family":"Yasmeen","sequence":"first","affiliation":[{"name":"Department of Community Medicine, Indira Gandhi Institute of Medical Sciences (IGIMS), Patna, Bihar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi","family":"Prasad","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Indira Gandhi Institute of Medical Sciences (IGIMS), Patna, Bihar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikash","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Indira Gandhi Institute of Medical Sciences (IGIMS), Patna, Bihar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Setu","family":"Sinha","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Indira Gandhi Institute of Medical Sciences (IGIMS), Patna, Bihar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shishir","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Indira Gandhi Institute of Medical Sciences (IGIMS), Patna, Bihar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Indira Gandhi Institute of Medical Sciences (IGIMS), Patna, Bihar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,10,11]]},"reference":[{"key":"R1-20260203","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","volume":"5","year":"2020","journal-title":"Nat Microbiol"},{"key":"R2-20260203","first-page":"513","article-title":"Rhino-orbital mucormycosis associated with COVID-19","volume":"29","author":"Mehta","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"key":"R3-20260203","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jinf.2020.02.016","article-title":"Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multi-center study in Wenzhou city, Zhejiang, China","volume":"80","author":"Yang","year":"2020","journal-title":"J Infect"},{"issue":"Suppl 1","key":"R4-20260203","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/cid\/cir866","article-title":"Epidemiology and clinical manifestations of mucormycosis","volume":"54","author":"Petrikkos","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R5-20260203","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3390\/jof7040298","article-title":"When uncontrolled diabetes mellitus and severe COVID-19 converge: The perfect storm for mucormycosis","volume":"7","author":"John","year":"2021","journal-title":"J Fungi"},{"key":"R6-20260203","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1128\/CMR.18.3.556-569.2005","article-title":"Novel perspectives on mucormycosis: Pathophysiology, presentation, and management","volume":"18","author":"Spellberg","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"R7-20260203","doi-asserted-by":"crossref","first-page":"101597","DOI":"10.1016\/j.bjid.2021.101597","article-title":"Is mucormycosis an inevitable complication of Covid-19 in India?","volume":"25","author":"Bhogireddy","year":"2021","journal-title":"Braz J Infect Dis"},{"key":"R8-20260203","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.4103\/jfmpc.jfmpc_1934_21","article-title":"A systematic review of mucormycosis cases in COVID-19: Is it an unholy trilogy of COVID-19, diabetes mellitus, and corticosteroids?","volume":"11","author":"Kumar","year":"2022","journal-title":"J Family Med Prim Care"},{"key":"R9-20260203","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/pgmj.2008.076463","article-title":"Invasive zygomycosis in India: Experience in a tertiary care hospital","volume":"85","author":"Chakrabarti","year":"2009","journal-title":"Postgrad Med J"},{"key":"R10-20260203","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/432579","article-title":"Epidemiology and outcome of zygomycosis: A review of 929 reported cases","volume":"41","author":"Roden","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R11-20260203","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/jac\/dkp430","article-title":"Forty-one recent cases of invasive zygomycosis from a global clinical registry","volume":"65","author":"Ruping","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"R12-20260203","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/jac\/dkr375","article-title":"The deferasirox-ambisome therapy for mucormycosis (Defeat Mucor) study: A randomized, double-blinded, placebo-controlled trial","volume":"67","author":"Spellberg","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"R13-20260203","first-page":"44","article-title":"Mucormycosis at a tertiary care centre in Gujarat, India","volume":"53","author":"Patel","year":"2010","journal-title":"Mycoses"},{"key":"R14-20260203","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s12281-013-0152-z","article-title":"Epidemiology of mucormycosis in India","volume":"7","author":"Chakrabarti","year":"2013","journal-title":"Curr Fungal Infect Rep"},{"key":"R15-20260203","doi-asserted-by":"crossref","first-page":"1416.e1","DOI":"10.1016\/j.cmi.2019.11.021","article-title":"A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India","volume":"26","author":"Patel","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"R16-20260203","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cmi.2018.07.011","article-title":"The epidemiology and clinical manifestations of mucormycosis: A systematic review and meta-analysis of case reports","volume":"25","author":"Jeong","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"R17-20260203","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/mmy\/myy060","article-title":"A prospective multicenter study on mucormycosis in India: Epidemiology, diagnosis, and treatment","volume":"57","author":"Prakash","year":"2019","journal-title":"Med Mycol"},{"key":"R18-20260203","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1017\/S0022215121000992","article-title":"Post coronavirus disease mucormycosis: A deadly addition to the pandemic spectrum","volume":"135","author":"Sharma","year":"2021","journal-title":"J Laryngol Otol"},{"key":"R19-20260203","first-page":"865","article-title":"The double trouble: COVID-19 associated mucormycosis a focused review and future perspectives","volume":"7","author":"Agnihotri","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"R20-20260203","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1038\/s41467-020-19741-6","article-title":"Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission","volume":"11","author":"Peckham","year":"2020","journal-title":"Nat Commun"},{"key":"R21-20260203","first-page":"168","article-title":"Risk factors for procurement of mucormycosis and its manifestations post COVID-19: A single arm retrospective Unicentric clinical study","volume":"8","author":"Gupta","year":"2022","journal-title":"Int J Otorhinolaryngol Head Neck Surg"},{"key":"R22-20260203","doi-asserted-by":"crossref","first-page":"e0256140","DOI":"10.1371\/journal.pone.0245556","article-title":"Sex differences in susceptibility, severity, and outcomes of coronavirus disease. 2019: Cross-sectional analysis from a diverse US metropolitan area","volume":"16","author":"Vahidy","year":"2021","journal-title":"PLoS One"},{"key":"R23-20260203","first-page":"811","article-title":"Exploiting the molecular basis of age and gender differences in outcomes of SARS-CoV-2 infections","volume":"12","author":"Mercatelli","year":"2021","journal-title":"Aging Dis"},{"key":"R24-20260203","doi-asserted-by":"crossref","first-page":"e148650","DOI":"10.1172\/JCI140491","article-title":"Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection","volume":"131","author":"Files","year":"2021","journal-title":"J Clin Invest"},{"key":"R25-20260203","first-page":"322ra10","article-title":"Mucorales-specific T cells emerge in the course of invasive mucormycosis and may be used as a surrogate diagnostic marker in high-risk patients","volume":"8","author":"Potenza","year":"2016","journal-title":"Sci Transl Med"},{"key":"R26-20260203","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/jof3030048","article-title":"Innate and adaptive immunity to mucorales","volume":"3","author":"Ghuman","year":"2017","journal-title":"J Fungi (Basel)"}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_358_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:17:30Z","timestamp":1787167050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_358_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_358_23","relation":{},"ISSN":["2249-4863","2278-7135"],"issn-type":[{"value":"2249-4863","type":"print"},{"value":"2278-7135","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"2023-02-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}